CELSION CORPORATION (NASDAQ:CLSN) Files An 8-K Unregistered Sales of Equity SecuritiesItem 3.02
Unregistered Sales of Equity Securities.
The information contained in Item 1.01 of this Current Report on Form 8-K in relation to the Representative Warrants and the shares of the Company’s Common Stock issuable upon the exercise thereof is incorporated herein by reference.
|
Item 9.01 |
Financial statements and Exhibits. |
(d)Exhibits.
|
ExhibitNo. |
Description |
|
1.1 |
Underwriting Agreement, dated as of October 27, 2017, by and between Celsion Corporation and Oppenheimer & Co. Inc. |
|
4.1 |
Form of Warrant. |
|
4.2 |
Form of Representative Warrant. |
|
5.1 |
Opinion of Sidley Austin LLP. |
|
23.1 |
Consent of Dixon Hughes Goodman LLP, independent registered accounting firm for Celsion Corporation. |
|
23.2 |
Consent of Stegman & Company, independent registered public accounting firm for Celsion Corporation. |
|
23.3 |
Consent of Sidley Austin LLP (included in Exhibit 5.1). |
Celsion CORP ExhibitEX-1.1 2 ex_98286.htm EXHIBIT 1.1 ex_98272.htm Exhibit 1.1 2,…To view the full exhibit click here
About CELSION CORPORATION (NASDAQ:CLSN)
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).